Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial

[1] Erratum W(2020)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Cancer J Clin 70 313-32

[2] Chen R(2016)Cancer statistics in China, 2015 Cancer J Clin 66 115-14

[3] Zheng PD(2014)Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial Lancet Oncol 15 305-52

[4] Baade S(2010)Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer Am J Clin Oncol 33 346-74

[5] Zhang H(2002)INT 0123 (Radiation Therapy Oncology Group 94 – 05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy J Clin Oncology: Official J Am Soc Clin Oncol 20 1167-7

[6] Zeng F(1999)Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85 – 01) Radiation Therapy Oncology Group Jama 281 1623-8

[7] Bray T(1992)Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus N Engl J Med 326 1593-84

[8] Conroy MP(1997)Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study J Clin Oncology: Official J Am Soc Clin Oncol 15 277-703

[9] Galais JL(2019)Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for locally advanced esophageal squamous cell Cancer: a Randomized, Multicenter, Phase III Clinical Trial J Clin Oncology: Official J Am Soc Clin Oncol 37 1695-7

[10] Raoul O(2022)Comparison of 3 paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell Cancer: a Randomized Clinical Trial JAMA Netw open 5 e220120-91

[1] Erratum W(2020)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Cancer J Clin 70 313-32

[2] Chen R(2016)Cancer statistics in China, 2015 Cancer J Clin 66 115-14

[3] Zheng PD(2014)Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial Lancet Oncol 15 305-52

[4] Baade S(2010)Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer Am J Clin Oncol 33 346-74

[5] Zhang H(2002)INT 0123 (Radiation Therapy Oncology Group 94 – 05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy J Clin Oncology: Official J Am Soc Clin Oncol 20 1167-7

[6] Zeng F(1999)Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85 – 01) Radiation Therapy Oncology Group Jama 281 1623-8

[7] Bray T(1992)Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus N Engl J Med 326 1593-84

[8] Conroy MP(1997)Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study J Clin Oncology: Official J Am Soc Clin Oncol 15 277-703

[9] Galais JL(2019)Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for locally advanced esophageal squamous cell Cancer: a Randomized, Multicenter, Phase III Clinical Trial J Clin Oncology: Official J Am Soc Clin Oncol 37 1695-7

[10] Raoul O(2022)Comparison of 3 paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell Cancer: a Randomized Clinical Trial JAMA Netw open 5 e220120-91